

FORM PTO 1449 (modified)				Atty. Docket No. X-12553	Serial No 09/856,451	RECEIVED	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Applicants John Michael Beals, et al.		OCT 11 2001	
				Filing Date May 22, 2001	Group 16001653	TECH CENTER 1600/2901	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
<i>Smu</i>	AA	5,252,714	10/12/93	J. Milton Harris, et al.	530	391.9	11/28/90
<i>Smu</i>	AB	4,002,531	01/11/77	Garfield P. Royer	195	68	01/22/76
	AC						
	AD						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub-class	Translation
<i>Smu</i>	BA	WO95/06058	02.03.95	PCT			yes no
	BB						
	BC						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>Smu</i>	CA		G.E. Francis, et al., International Journal of Hematology, PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques, Vol. 68(1), pages 1-18, 1998.				
	CB		C. Delgado, et al., Pharmaceutical Sciences, Polymer-derivatized Proteins: Analytical and Preparative Problems, Vol. 3(1), pages 59-66, 1997.				
	CC		G.E. Francis, et al., Journal of Drug Targeting, Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting, Vol. 3(5), pages 321-340, 1996.				
	CD		Gillian E. Francis, Innovations in Pharmaceutical Technology, PEGylation technology, pages 41-45.				
	CE		Farooq Malik, Open University, Volume 58/01-C of Dissertation Abstracts International, Construction and characterization of polyethylene glycol-modified cytokines (monomethoxypolyethylene glycol), page 208, 1993.				
	CF		Cristina Delgado, et al., Critical Reviews in Therapeutic Drug Carrier Systems, The uses and Properties of PEG-Linked Proteins, Vol. 9(3,4), pages 249-304, 1992.				
<i>V</i>	CG		Gillian E. Francis, et al., Stability of Protein Pharmaceuticals, Part B: In vivo Pathways of Degradation and Strategies for Protein Stabilization, eds, Ahern TJ and Manning MC, Plenum Press, New York, PEG-Modified Proteins, 1992.				
EXAMINER <i>Deborah M. Noakes</i>				DATE CONSIDERED <i>12/30/2005</i>			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

RECEIVED